1. Introduction {#s0005}
===============

Diabetes mellitus is a growing global epidemic with more than 439 million projected to be affected by 2030 [@bb0015]. Oral diseases, such as periodontitis, dental caries, fungal infection, xerostomia, and salivary gland dysfunction, are all major complications associated with diabetes [@bb0030], [@bb0085]. Saliva contains a number of components, such as electrolytes, multiple buffering systems, digestive enzymes, lubricant glycoproteins, and antimicrobial proteins, to maintain oral homeostasis and preserve the health of the teeth and oral mucosa and prevent infection. Therefore, salivary dysfunction may account for a number of the oral diseases associated with diabetes and may be a risk factor for these patients. Indeed, decreased salivary flow rates have been documented in clinical cohort studies and animal models of diabetes [@bb0085], [@bb0115], [@bb0155]. Further, a limited number of studies have reported changes in saliva composition, such as amylase, total protein and antimicrobial proteins, in diabetic patients [@bb0030], [@bb0070], [@bb0115], [@bb0135].

Human salivary statherin is a low molecular weight phosphoprotein, containing 43 amino acids, that functions to inhibit spontaneous precipitation of calcium and phosphate salts (primary precipitation) from saliva and the growth of hydroxyapatite crystals (secondary precipitation) on the surface of the teeth [@bb0090], [@bb0100]. In addition, statherin is a major component of the "acquired" dental pellicle and functions to regulate mineralization at the surface through binding of its hydrophilic N-terminal domain to hydroxyapatite and selection of oral microorganisms that bind to the pellicle through its C-terminal domain [@bb0035], [@bb0090], [@bb0100]. Further, the level of statherin in whole saliva has been reported to be higher in caries-free patients than in caries-susceptible patients and those with elevated decayed, missing, and filled teeth (DMFT) indices [@bb0145]. Based on these observations, it is generally believed that statherin plays a critical role in protecting oral tissues from a number of common dental disorders (e.g., periodontal diseases, dental caries and oral mucosa infections) [@bb0055], [@bb0125].

Previous studies have shown that oral health in patients with type 2 diabetes is compromised and that many of the problems these patients have are attributable to reduced salivary production or secretion and alterations in the composition of their saliva [@bb0085], [@bb0115], [@bb0155]. In other studies, statherin expression in labial, submandibular, and parotid gland tissue, obtained from control and diabetic (type 2) patients undergoing head and neck tumor resection, was examined using immunogold labeling and transmission electron microscopy (TEM). Statherin immunoreactivity was detected in small vesicles, diffusely localized throughout the cytoplasm of labial serous cells, and in secretory granules of serous acinar cells in both submandibular and parotid glands [@bb0055], [@bb0060], [@bb0065]. Detailed statistical analyses revealed that the number of stained particles was significantly lower in tissues of diabetic subjects than non-diabetic controls. Recent proteome and peptidome analyses of saliva from children with type 1 diabetes also suggest a relatively lower production of statherin than those in controls [@bb0005].

Since the earlier studies, mentioned above, demonstrated decreased production of statherin in salivary gland tissue (type 2 diabetics) and saliva (type 1 diabetics), the current study aimed to determine whether there are measurable differences in salivary statherin from sublingual/submandibular and parotid glands from normal (n = 24) and type 2 diabetic (n = 24) middle aged subjects. Changes in statherin production were also evaluated for correlation with fasting blood glucose and HbA1c levels and DMFT indices. The overall goal was to evaluate whether salivary statherin had potential as a marker of salivary dysfunction, oral health, and overall disease activity in type 2 diabetes.

2. Materials and methods {#s0010}
========================

2.1. Subjects {#s0015}
-------------

A total of 48 subjects, 24 diabetic and 24 healthy age- and gender-matched controls, were randomly selected from 1322 subjects in the Oral Health: San Antonio Longitudinal Study of Aging (OH: SALSA) database [@bb0030] which included both Mexican American and European American ethnic groups. The number of subjects to be included in the study was estimated using a power analysis (effect size = 0.85,αerror = 0.05, power = 0.80) and based on a preliminary study of PS. The study protocol was approved by the Institutional Review Board of the University of Texas Health Science Center at San Antonio and informed consent was obtained from each participant. Diabetic subjects were identified based on fasting plasma glucose levels \> 180 mg/dL. Control subjects (non-diabetic), with comparable age and gender to the diabetic cohort, were identified by having no major health problems and fasting plasma glucose levels \< 110 mg/dL. Some of the control subjects, however, were taking anti-cholesterolemic or anti-hypertensive medications. Body mass index (BMI), HbA1c, and oral health status were also obtained for both groups, but not used as selection criteria.

2.2. Saliva collection {#s0020}
----------------------

Parotid saliva (PS) and sublingual/submandibular saliva (SS) production were stimulated and collected as previously described [@bb0030]. In brief, PS was collected using a modified Carlson--Crittenden cup, while SS was collected using a micropipette connected to a mini-vacuum pump. Stimulation of saliva production was achieved by swabbing the lateral surfaces of the tongue with 0.1 M (≈ 2%, w/v) citric acid every 30 s. PS was collected for 5 min and SS for 3 min. Salivary flow rate was calculated by dividing the total volume of saliva obtained by the length of time taken to collect it and expressing the result as mL/min. Saliva samples were divided into 100 μL aliquots and stored at − 80 °C until analyzed.

2.3. Immunoblot analysis {#s0025}
------------------------

Salivary statherin levels were determined using a previously described method with some modification [@bb0030], [@bb0150]. Saliva (PS and SS) samples were thawed and ethylenediamine tetraacetic acid (EDTA) was added to a final concentration of 0.5 mM to minimize aggregate formation. Following a series of pilot experiments, the volume of saliva required to obtain an optimal statherin signal in the immunoblot analysis was found to be 0.125 μL for both control and diabetic samples. Total protein content of the saliva was determined by measuring absorbance at 215 nm using a DU® spectrophotometer (Beckman Coulter, CA, USA) [@bb0130]. Bovine serum albumin was used as a standard.

Saliva samples were separated on precast 4--20% SDS-PAGE gels (Mini-PROTEAN® TGX™, Bio-Rad Laboratories, Inc., CA, USA) and then transferred to polyvinylidene difluoride membranes (Millipore Corp, Bedford, MA). The membranes were immunoblotted with a primary antibody against human statherin (1:2000 dilution; STATH Polyclonal Antibody \[catalog \#19724-1-AP\], Proteintech, IL, USA) at 4 °C overnight, followed by incubation with horseradish peroxidase-labeled secondary antibody (1:10,000) (GE Healthcare Life Sciences, PA, USA). The statherin immunoreactive band was visualized using an ECL detection kit (ECL Advance™ Western Blotting Detection Kit, GE Healthcare, Buckinghamshire, UK) and band images were acquired and analyzed with an AutoChemi system (UVP, Inc., CA, USA). Gray-scale values for statherin-positive bands were quantified using Scion Image software (Scion Corporation, MD, USA).

2.4. Quantification of statherin {#s0030}
--------------------------------

To compensate for variations in immunoblotting, one PS sample was selected from the normal controls that produced an average level of band intensity after SDS-PAGE and immunoblotting. The integrated gray value of this standard (0.125 μL saliva) was assigned an arbitrary value of 100. Statherin levels in all samples were calculated relative to this PS standard and are reported as the percent (%) statherin level for a particular PS or SS sample.

To normalize the data, the % statherin level (calculated above) was divided by the protein content in the saliva sample (% statherin level divided by μg protein/μL saliva). To obtain an estimate of the rate of statherin secretion in PS and SS, the % statherin level was multiplied by the measured salivary flow rate (mL/min).

2.5. Statistical analysis {#s0035}
-------------------------

A power analysis was performed using the statistical software, G\*Power (version 3.1.9.2) [@bb0040], [@bb0045] to determine the appropriate number of subjects to include in the study. The Mann--Whitney U-test was used for comparing data from control and diabetic subjects. Spearman\'s rank correlation coefficient was used for the test of correlation between statherin level and HbA1c and blood glucose levels. These statistical analyses were carried out using PASW Statistics 17.0 software (SPSS, Inc., IL, USA). A p-value less than 0.05 was considered statistically significant.

3. Results {#s0040}
==========

The demographics of the control and diabetic subjects are shown in [Table 1](#t0005){ref-type="table"}. The average age of the subjects in both groups was nearly identical and the male/female ratio was identical in each. In diabetic subjects, median body mass index (BMI) and HbA1c level were statistically higher when compared with controls (p = 0.049 and p \< 0.001, respectively). Salivary flow rates of diabetic subjects were less than controls for the SS (p = 0.021) with no apparent changes in the PS (p = 0.428). Interestingly, the total protein concentration in SS was also significantly decreased (p \< 0.001) in diabetics but was unchanged in PS (p = 0.404).

Statherin was easily detected in minute amounts of saliva, using immunoblot analysis ([Fig. 1](#f0005){ref-type="fig"}A). The level of statherin in PS was significantly decreased in diabetics as compared with controls (\~ 45% reduction; p = 0.031; [Fig. 1](#f0005){ref-type="fig"}B); in contrast, the statherin level in SS from diabetics was also lower, but this difference was not statistically significant (p = 0.109; [Fig. 1](#f0005){ref-type="fig"}B). Correlation analysis revealed a negative correlation between PS statherin levels and serum HbA1c (p = 0.012; [Fig. 2](#f0010){ref-type="fig"}A). Similarly, a correlation was also demonstrated between PS statherin levels and fasting glucose (p = 0.021; [Fig. 2](#f0010){ref-type="fig"}C). In contrast, there was no significant correlation between statherin levels and HbA1c or fasting glucose in SS ([Fig. 2](#f0010){ref-type="fig"}B and D).

When statherin levels were normalized to total protein in the saliva, the proportion of statherin in PS total protein was significantly lower in diabetics than in healthy controls (p = 0.032; [Table 2](#t0010){ref-type="table"}). In contrast, the ratio of statherin to total protein in SS was not significantly different between diabetics and controls. On the other hand, the amount of statherin secretion per unit time in SS was significantly decreased in diabetics compared to controls (p = 0.016), but this difference was not observed for statherin secretion in PS ([Table 2](#t0010){ref-type="table"}).

We also evaluated the DMFT index for the control and diabetic subjects in this study. Both DMFT for the crown (DMFT-c) and root (DMFT-r) are higher in diabetic patients than controls ([Fig. 3](#f0015){ref-type="fig"}). The correlation studies showed that DMFT-r is negatively correlated with SS salivary flow rates (p = 0.026). No other correlation between DMFT-r, DMFT-c, and statherin levels was observed.

4. Discussion {#s0045}
=============

We have previously shown that salivary flow rates and several antimicrobial proteins are altered in non-insulin-dependent (type 2) diabetic patients [@bb0030]. In the current study, we determined the level of salivary statherin in poorly controlled type 2 diabetic patients (based on HbA1c and fasting glucose values) compared to healthy age- and gender-matched controls. The results show that statherin levels in diabetic patients are significantly decreased in PS and that a negative correlation exists between PS statherin levels and HbA1c and fasting glucose levels. We have also shown that SS salivary flow rates are reduced in diabetic patients and diabetic patients have higher DMFT scores.

Patients with diabetes (both types 1 and 2) are known to have altered salivary gland function such as decreased flow rates and altered composition [@bb0010], [@bb0030], [@bb0070], [@bb0115], [@bb0135]. In the present study, we observed that stimulated SS flow rates were significantly decreased in diabetic subjects. We did not detect any significant decrease in stimulated PS flow rates in diabetes as indicated by some previously published studies [@bb0010]. The reason for these discrepancies in measures of salivary function with diabetes may be due to cohort effects, large individual variations, and sample sizes. To the best of our knowledge, this study is the first to document decreased statherin levels in glandular saliva of type 2 diabetics. Previously, a quantitative peptidomic study of whole saliva suggested a decrease in salivary statherin levels of type 1 diabetic patients [@bb0005]. A lower immunoreactive statherin level in parotid, submandibular and labial glands from diabetic patients has also been reported using an immunogold transmission electron microscopy approach [@bb0055], [@bb0060]. The effect of diabetes on statherin secretion appears to be more pronounced on PS than SS as statistically significant differences were only observed in PS (see [Table 2](#t0010){ref-type="table"}, % statherin levels and % statherin levels normalized to protein). Since no differences in PS flow rate and total protein concentrations were found between healthy controls and diabetics ([Table 1](#t0005){ref-type="table"}), statherin levels in PS appear to be directly influenced by the hyperglycemia of diabetes mellitus. This conclusion is further supported by our results showing a negative correlation between PS statherin levels and HbA1c and fasting glucose levels (see [Fig. 2](#f0010){ref-type="fig"}). However, prior studies have reported that immunoreactive statherin is only present in serous acinar cells. The less pronounced effect of diabetes on statherin levels in SS may be due to differences in the acini of these two glands. In addition, in the present study, the effect of diabetes on statherin production by individual submandibular and sublingual glands could not be evaluated as we did not collect separate saliva samples from these two glands [@bb0140].

Our results further demonstrate that SS flow rate and total protein concentrations are significantly lower in diabetic patients. Prior studies have shown that statherin concentrations increase with salivary flow rates [@bb0080]. The decrease in median statherin levels in SS of diabetic patients, although not significant, may relate to the significantly reduced salivary flow rates found in diabetes (see [Fig. 1](#f0005){ref-type="fig"}). Currently, the cellular and molecular mechanisms, responsible for inducing salivary gland dysfunction in diabetes, are unclear. Morphological, immunolabeling and functional studies of salivary glands, using experimental animal models and clinical samples, indicate that diabetes leads to changes in the autonomic nervous system [@bb0110], [@bb0155], lower expression of cyclic AMP receptors and secretory proteins (e.g., amylase, proline-rich proteins, and mucins) [@bb0105], [@bb0120], and structural changes in cellular organelles (e.g., increased acinar and secretory granule area, reduced mitochrondria size, and increased membrane folding) [@bb0095], [@bb0155] as compared to normal salivary gland cells. Whether these alterations contribute to, or are associated with, differences in salivary statherin levels between diabetes and healthy controls require further study. Nevertheless, statherin, an abundant salivary protein as our results demonstrate, can serve as a marker for studying the effect of diabetes on salivary function.

Statherin is a major salivary protein with multiple physiological functions. Reduced statherin levels in PS and total statherin secretion in SS can put diabetic patients at risk for a number of oral diseases. Indeed, statherin levels have been associated with elevated decayed, missing, and filled teeth/surfaces (DMFT/DMFS) indices [@bb0145]. While a direct correlation between statherin levels and DMFTs were not found in the current study, the DMFT index for crown and roots were both higher in diabetic patients compared to the healthy non-diabetic controls and confirmed previous studies demonstrating an association between diabetes and DMFT [@bb0075], [@bb0085]. Thus far, the association of dental caries and diabetes has not been well documented [@bb0085]. In contrast, diabetic patients are known to be at a higher risk for more severe periodontal diseases [@bb0085]. The lower salivary flow rates and periodontal diseases among diabetic patients may partially explain the higher DMFT-c and DMFT-r in diabetic patients [@bb0050], [@bb0085]. In our cohort, the differences in DMFTs may derive from missing teeth since the diabetic group has significantly more missing teeth (data not shown). Whether the missing teeth are due to periodontal disease or caries is currently unclear. Regardless, the lower statherin concentration and secretions in this study suggest a potential major risk for oral diseases in diabetic patients.

In prior studies, salivary statherin levels have been quantified with chromatography, ELISA and immunodiffusion assays using investigator prepared statherin or its antibodies [@bb0020], [@bb0080], [@bb0090]. In this study, we developed a highly sensitive method for specifically quantifying statherin in saliva using gel electrophoresis and immunoblotting with commercially available antibodies. The immunoblot analysis allowed the relative quantification of statherin with \< 0.5 μg total salivary protein (\~ 0.125 μL saliva). The primary antibody used in this study does not cross-react with rodent saliva or salivary gland tissue as predicted by phylogenetic studies [@bb0025]. The commercially available antibodies open the way for developing highly sensitive antibody-based assays for measuring statherin and exploring the role of statherin in the pathogenesis of oral diseases.

In conclusion, we have shown that statherin levels in PS and the statherin secretion rate in SS are decreased in poorly controlled diabetic patients compared to non-diabetic controls. In addition, statherin levels in PS were negatively correlated with blood glucose and HbA1c levels. We have further demonstrated that diabetic patients have a higher DMFT index and lower salivary flow rates. Alterations in statherin level and secretion, in combination with compromised salivary flow rates, may account for the higher incidence of oral complications in diabetic patients. Oral diseases, especially periodontal diseases have been linked to diabetic control, further emphasizing that oral health maintenance should be an integral part of diabetic management [@bb0085].
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![Statherin levels in the saliva of patients with diabetes and healthy age- and gender-matched controls as measured by immunoblot analysis. Stimulated parotid saliva (PS) and sublingual/submandibular saliva (SS) were collected as described in [Materials and methods](#s0010){ref-type="sec"} section and then subjected to 4--20% gradient SDS-PAGE, followed by Western blotting for statherin, and quantification using Scion Image software. Panel A: a representative gel of salivary statherin in 0.125 μL saliva (PS and SS) collected from diabetic patients and controls. ST: prescreened PS sample used for quantitation (see [Materials and methods](#s0010){ref-type="sec"} section). Panel B: statherin levels in saliva were determined by converting the stained region of the immunoblot (for each sample) into a density value. The relative statherin level was expressed as the ratio of statherin band density for an individual subject to the standard PS sample run on each gel. The box plots show the 1st and 3rd quartiles, median (horizontal line between the 1st and 3rd quartiles) and outliers (open circles) \[more than 1.5 × (3rd--1st quartiles)\].](gr1){#f0005}

![Correlation between salivary statherin levels and fasting blood glucose and HbA1c levels in patients with diabetes and healthy age- and gender-matched controls. Normalized statherin levels in stimulated parotid saliva (PS, panels A and C) and stimulated submandibular/sublingual saliva (SS, panels B and D) were plotted against HbA1c (panels A and B) or fasting blood glucose (panels C and D) levels. A significant negative correlation was found between PS statherin and HbA1c (panel A) and fasting blood glucose (panel C).](gr2){#f0010}

![Decayed, missing and filled teeth (DMFT) index for tooth crown (DMFT-c) or dental root (DMFT-r) in patients with diabetes and healthy age- and gender-matched controls. The box plots represent the 1st and 3rd quartiles, median (horizontal line between the 1st and 3rd quartiles) and outliers (open circles) \[more than 1.5 × (3rd--1st quartiles)\].](gr3){#f0015}

###### 

Demographics of the study subjects.

                                Control (n = 24)    Diabetics (n = 24)     p value
  ----------------------------- ------------------- ---------------------- ------------
  Age (years)                   67 (58.8--70.0)     67.5 (58.3--70.8)      --
  Gender (male/female)          11/13               11/13                  --
  BMI (kg/m^2^)                 26.5 (25.0--29.3)   29 (26.3--35.8)        0.049
  Fasting glucose (mg/dL)       94.5 (89.0--98.3)   199.5 (193.0--265.5)   --
  HbA1c (%)                     5.5 (5.1--5.9)      9.0 (8.0--12.7)        \< 0.001
  Salivary flow rate (mL/min)                                              
   PS                           0.29 (0.11--0.43)   0.31 (0.19--0.53)      0.428 (NS)
   SS                           0.42 (0.30--0.51)   0.24 (0.18--0.45)      0.021
  Total protein (μg/μL)                                                    
   PS                           1.99 (1.51--2.98)   1.88 (1.58--2.23)      0.404 (NS)
   SS                           1.97 (1.60--2.56)   1.52 (1.13--1.79)      \< 0.001

The data shown are the median value for each parameter; the 25th and 75th percentile values are shown in parentheses.

Abbreviations: PS: stimulated parotid saliva, SS: stimulated submandibular/sublingual saliva.

p value determined using the non-parametric Mann--Whitney U-test.

--: not statistically evaluated for differences.

NS: not significant.

###### 

Salivary statherin in diabetic and control subjects.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                      Statherin level\                         Statherin level normalized to protein\    Total statherin secretion\                        
                      (% statherin)                            (% statherin / μg protein/μL saliva)      (% statherin / μg protein/μL saliva) × (mL/min)   
  ------------------- ---------------------------------------- ----------------------------------------- ------------------------------------------------- ----------------
  PS                  Control subjects                         97.0\                                     43.19\                                            22.97\
                                                               (59.5--127.0)                             (29.67--63.12)                                    (15.38--33.28)

  Diabetic subjects   53.0[⁎](#tf0005){ref-type="table-fn"}\   26.26[⁎](#tf0005){ref-type="table-fn"}\   15.37\                                            
                      (26.5--119.0)                            (13.51--53.17)                            (6.93--27.50)                                     

  SS                  Control subjects                         25.5\                                     14.06\                                            11.41\
                                                               (13.8--57.5)                              (6.34--25.46)                                     (5.21--21.88)

  Diabetic subjects   13.0\                                    8.55\                                     3.38[⁎](#tf0005){ref-type="table-fn"}\            
                      (4.0--44.0)                              (4.00--31.66)                             (1.25--12.69)                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The data shown are the median value for each parameter; the 25th and 75th percentile values are shown in parentheses.

The % statherin level in a 0.125 μL aliquot of saliva was calculated in relation to the amount measured in a pre-screened PS sample of equal volume as described in [Materials and methods](#s0010){ref-type="sec"} section. These data were then normalized to the total protein content in a μL saliva (=% statherin level/total protein). Total statherin secretion was calculated by multiplying the % statherin level/total protein in a μL saliva by salivary flow rate (mL/min).

Abbreviations: PS: stimulated parotid saliva, SS: stimulated submandibular/sublingual saliva.

p \< 0.05 vs. control subjects.
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